je.st
news
Home
› Acceleron Highlights Phase 3 Studies, New Clinical Results And Research Strategies At Research And Development Day Event
Acceleron Highlights Phase 3 Studies, New Clinical Results And Research Strategies At Research And Development Day Event
2015-11-03 04:51:04| drugdiscoveryonline Home Page
Acceleron Pharma Inc., a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, recently announced the phase 3 clinical trial designs for the luspatercept program in myelodysplastic syndromes (“MEDALIST” study) and beta-thalassemia (“BELIEVE” study), phase 1 preliminary results from the ACE-083 program, and its new IntelliTrapdrug discovery platform
Tags: day
results
research
development
Category:Biotechnology and Pharmaceuticals